Federal prosecutors have charged Indivior with engaging in a multibillion-dollar fraudulent scheme to increase prescriptions of Suboxone Film, a medicine used to treat addiction to opioid and narcotics.

In an indictment filed on Wednesday, the Justice Department alleged the drug maker deceived doctors and payers into believing the medicine was safer and less prone to diversion and abuse than other such treatments, although the company lacked any scientific evidence to support those claims. The indictment also claimed the company used a telephone and Internet program to connect patients struggling with addiction to doctors who were inappropriately prescribing opioids and at high rates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy